Tarcocimab and Tabirafusp for Wet Age-Related Macular Degeneration

DAYBREAK is a non-inferiority Phase 3 in treatment-naive wet AMD comparing tarcocimab and KSI-501 vs aflibercept (~690 pts). Prior DAYLIGHT study already met non-inferiority on BCVA with monthly tarcocimab vs aflibercept Q8W. Enhanced formulation, treat-to-dryness with loading doses favor success. KSI-501 Phase 1b APEX showed strong BCVA gains. Anti-VEGF non-inferiority trials in wet AMD have high historical success rate. Main risk: durability arm could underperform. Topline expected Sept 2026, beyond Aug 1 primary completion.

Phase 3 wet AMD study uses a standard, objective BCVA change endpoint at 48 weeks with aflibercept control and is active/not recruiting near completion, supporting executable readout. However active-control vision efficacy is a high bar and fields provide no prior efficacy or alpha details, limiting upside.

Phase 3, active not recruiting, wet AMD, BCVA mean change at Wk48 primary endpoint vs aflibercept comparator; standard gold-standard endpoint and timeline (66 days to completion) support moderate positive result odds but no design details, powering, or prior data in fields.

DAYBREAK tests tarcocimab and KSI-501 vs. aflibercept in wet AMD for non-inferior BCVA change. Past Kodiak failures involved rigid extended dosing; DAYBREAK fixes this via individualized treat-to-dryness dosing (Q4W-Q24W) after 4 loading doses, structurally protecting vision. DAYLIGHT already showed tarcocimab's non-inferiority in wet AMD. Two arms give dual shots on goal.

Phase 3 trial of two Kodiak agents vs aflibercept in wet AMD. Prior Phase 3 failures for tarcocimab (GLEAM/GLIMMER) raise concern; tabirafusp is a novel bispecific but unproven. Non-inferiority design may lower bar, but high risk of missing efficacy or safety. Estimated 35% success probability.

Tarcocimab previously FAILED the Phase 3 DAZZLE trial in wet AMD due to inflammation issues eroding BCVA non-inferiority vs aflibercept. Anti-PDGF combinations (Fovista, rinucumab) also have a dismal Phase 3 track record in ophthalmology. Tabirafusp is novel but carries similar mechanistic risk. Kodiak's small size and prior pivotal failure weigh heavily. Positive outcome unlikely given these compounding risk factors.

Kodiak's Tarcocimab/Tabirafusp targets dual pathways (VEGF/Ang2) in wet AMD. Phase 2 data showed promising durability and visual acuity gains. Phase 3 design mirrors successful predecessors. While competition is fierce, the mechanistic rationale and prior signals support a positive BCVA outcome vs aflibercept.

Phase 3, active not recruiting, with 66 days to primary completion. Wet AMD trials use standard BCVA change at 48 weeks, but the combo of tarcocimab tedromer, tabirafusp tedromer and aflibercept lacks published Phase 2 efficacy data. This creates moderate uncertainty; the chance of a positive outcome is modestly above 50%.

Kodiak's tarcocimab previously failed Phase 3 in diabetic macular edema (GLOW study, 2023), showing no BCVA benefit vs aflibercept. Wet AMD is a more competitive space with established biosimilars. Novel antibody biopolymer platform (ABC) has mixed validation. Active Not Recruiting with 66 days to completion suggests data may already be collected, limiting upside surprise. Primary endpoint is standard BCVA at 48 weeks, but prior failure in related indication raises skepticism about mechanism. Sponsor disclosure risk is moderate given small-cap status.

Phase 3 wet AMD trial with gold-standard BCVA endpoint and established comparator (aflibercept). Novel biopolymer conjugate technology with two pipeline candidates suggests internal confidence. 66 days to readout. Wet AMD Phase 3 trials historically succeed when prior phases are positive, and no trial design red flags present.